HIV Drugs Market Report 2026

HIV Drugs Market Overview

• HIV Drugs market size has reached to $36.55 billion in 2025 • Expected to grow to $43.08 billion in 2030 at a compound annual growth rate (CAGR) of 3.4% • Growth Driver: Elevated Awareness Initiatives Driving HIV Drug Market Growth • Market Trend: Strategic Partnerships in the HIV Drugs Market to Manufacture Lenacapavir • North America was the largest region in 2025 and Middle East is the fastest growing region.

What Is Covered Under HIV Drugs Market?

HIV drug refers to an antiretroviral drug that is frequently used to treat HIV. HIV medications prevent the spread of the human immunodeficiency virus (HIV) or other retroviruses in the body. HIV can cause AIDS if it is not treated (acquired immunodeficiency syndrome). Currently, there is no cure that works well. The main types of HIV drugs are nucleoside reverse transcriptase inhibitors (NRTs), non-nucleoside reverse transcriptase inhibitors (NNRT’s), protease inhibitors, integrate inhibitors, fusion inhibitors, chemokine receptor inhibitors, and others. Nucleoside reverse transcriptase inhibitors (NRTIs) are structural nucleoside analogs of DNA nucleotides that inhibit HIV-1 RT and viral replication by preventing reverse transcription of the HIV genome. The drugs are administered through oral and parenteral methods that are used by hospital pharmacies, retail pharmacies, online pharmacies, and others.

What Is The HIV Drugs Market Growth Forecast?

The hiv drugs market size is expected to see steady growth in the next few years. It will grow to $43.08 billion in 2030 at a compound annual growth rate (CAGR) of 3.4%. The growth in the forecast period can be attributed to emergence of long-acting therapies, advancement in precision medicine, integration of ai in drug discovery, expansion of healthcare access in emerging markets, development of combination antiretroviral therapies. Major trends in the forecast period include personalized antiretroviral therapy, long-acting injectable hiv drugs, hiv drug resistance monitoring, combination therapy development, access programs in emerging markets.

Global HIV Drugs Market Segmentation

1) By Type: Nucleoside Reverse Transcriptase Inhibitors (NRT’s), Non- Nucleoside Reverse Transcriptase Inhibitors (NNRT’s), Protease Inhibitors, Integrase strand transfer inhibitors (INSTIs), Other Types 2) By Administration: Oral, Parenteral 3) By Application: Hospital Pharmacies, Retail Pharmacies, Other Applications Subsegments: 1) By Nucleoside Reverse Transcriptase Inhibitors (NRTIs): Zidovudine (AZT), Lamivudine (3TC), Abacavir (ABC), Tenofovir disoproxil fumarate (TDF) 2) By Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs): Efavirenz (EFV), Nevirapine (NVP), Etravirine (ETR), Rilpivirine (RPV) 3) By Protease Inhibitors (PIs): Ritonavir (RTV), Lopinavir (LPV), Darunavir (DRV), Atazanavir (ATV) 4) By Integrase Strand Transfer Inhibitors (INSTIs): Raltegravir (RAL), Dolutegravir (DTG), Bictegravir (BIC) 5) By Other Types: Entry Inhibitors, Fusion Inhibitors, Combination Therapies

What Are The Drivers Of The HIV Drugs Market?

Increasing awareness among people regarding the diagnosis and treatment of HIV disease acts as an important driver for the growth of the HIV drug market. Awareness of HIV refers to people’s knowledge of its diagnosis, treatment, and prevention to enable timely detection and management. Increasing awareness of HIV promotes early testing and treatment, improving health outcomes and reducing transmission. HIV drugs help raise awareness by highlighting the importance of treatment and encouraging people to get tested and seek care, reinforcing public understanding of HIV management and prevention. For instance, in July 2024, according to the United Nations International Children's Emergency Fund (UNICEF), a US-based humanitarian aid organization, an estimated 40.0 million people were living with HIV worldwide in 2023. Therefore, increasing awareness among people regarding the diagnosis and treatment of HIV disease acts as an important driver for the growth of the HIV drug industry. The increased government spending is expected to boost the growth of the HIV drugs market going forward. Government spending, also known as public spending or government expenditure, refers to the total amount of funds that a government allocates and disburses to finance its various functions, programs, and services. Increased government funding supports various aspects of the HIV drug market, from research and development to improving access, and awareness, and reducing the societal and economic burden of the disease. These investments have a positive impact on the market's growth and overall effectiveness in addressing the HIV or AIDS pandemic. For instance, in March 2023, according to the Budget of the U.S. Government report, published by the US government, in Joe Biden's Fiscal Year (FY) 2024 budget proposal, around $850 million was allocated in funding for the CDC, HRSA, IHS, and NIH to sustain and expand the implementation of the Ending the HIV epidemic in the U.S. initiative. This marks a substantial increase of $277 million (48%) compared to the funding level enacted in FY23. Therefore, the increased government spending is driving the growth of the HIV drug industry.

Key Players In The Global HIV Drugs Market

Major companies operating in the hiv drugs market are Gilead Sciences Inc., Johnson & Johnson, Merck & Co. Inc., Boehringer Ingelheim International GmbH, Cipla, Aurobindo Pharma, AbbVie, Emcure Pharmaceuticals, Micro Labs Limited, Northeast Pharmaceutical Group Co. Ltd, Dr. Reddy's Laboratories Ltd., Sun Pharmaceutical Industries Ltd, Strides Arcolab Limited, Hetero Labs Limited, Shanghai Desano Bio-pharmaceutical Co., Anhui Biochem Biopharmaceutical Co. Ltd., Shanghai Xinxing Medicine Co. Ltd., China Meheco Xinxing Pharma Co. Ltd., CytoDyn Inc., Janssen Pharmaceutical, Roche Laboratories, Mylan N.V., Bristol-Myers Squibb Company, F. Hoffmann-La Roche AG, Teva Canada, ViiV Healthcare Canada, GSK, Abbott Laboratories, Aspen Pharmacare Limited, Pharmacare Ltd.

Global HIV Drugs Market Trends and Insights

Major companies in the HIV drugs market are forming strategic partnerships to manufacture Lenacapavir to accelerate drug development, expand access to treatments, and enhance their global market presence. Lenacapavir is a first-in-class HIV-1 capsid inhibitor that works effectively in combination with other antiretrovirals and targets multiple stages of the HIV lifecycle, making it a promising option for patients with limited treatment alternatives. For instance, in August 2023, Dr. Reddy's Laboratories, an India-based pharmaceutical company, and Hetero, an India-based pharmaceutical company partnered with Gilead Sciences Inc. With this partnership, Dr. Reddy's Laboratories and Hetero aims to manufacture and distribute the HIV drug lenacapavir in 120 primarily low- and lower-middle-income countries (LMICs). This initiative aims to broaden access to this innovative treatment, which is particularly beneficial for heavily treatment-experienced patients with multi-drug-resistant HIV. Gilead Sciences Inc. is a US-based biopharmaceutical company.

Regional Insights

North America was the largest region in the HIV drugs market share in 2025. Middle East is expected to be the largest growing region in the global HIV drug market during the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the HIV Drugs Market?

The HIV drug market consists of sales of Tivicay, Triumeq, Truvada, and Vemlidy. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the HIV Drugs Market Report 2026?

The hiv drugs market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the hiv drugs industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.